Publication | Closed Access
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
204
Citations
0
References
2009
Year
Advanced Gastric CancerCancer ManagementPathologyMay 30OncologyGastrointestinal OncologyCancer Cell BiologyClinical OncologyToga TrialRadiation OncologyMolecular OncologyCancer ResearchFinal TextCancer TreatmentMalignant DiseaseTumoral PathologyImmune Checkpoint InhibitorMedicinePhase Iii Study
LBA4509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]